UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s What Happened
by Renee Jackson · The Cerbat GemUCB SA (OTCMKTS:UCBJF – Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $317.94, but opened at $306.50. UCB shares last traded at $306.50, with a volume of 2 shares changing hands.
Analyst Ratings Changes
A number of brokerages recently weighed in on UCBJF. Stephens reaffirmed an “overweight” rating on shares of UCB in a research note on Thursday, January 15th. Barclays reaffirmed an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a research report on Monday, December 8th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy”.
View Our Latest Report on UCBJF
UCB Trading Down 0.7%
The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average of $286.05 and a 200-day moving average of $260.39.
About UCB
UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.
Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.